CARGO Therapeutics, Inc. Common Stock
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CARGO Therapeutics, Inc. CARGO Therapeutics, Inc. (NASDAQ:CRGX) operates as a clinical-stage biotechnology company focused on designing, engineering, and developing next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer patients, primarily targeting B-cell malignancies in the United States; its lead product candidates include CRG-023, a tri-specific CAR T therapy targeting CD19, CD20, and CD22 antigens currently in Phase 1 clinical development, firicabtagene autoleucel (firi-cel), an autologous CD22 CAR T-cell therapy in a potentially pivotal Phase 2 trial for relapsed/refractory large B-cell lymphoma, and an allogeneic platform featuring a universal vector solution to limit immune rejection and enable off-the-shelf CAR T products compatible with existing autologous processes. The company, formerly known as Syncopation Life Sciences, Inc., was incorporated in 2019, renamed in September 2022, and is headquartered in San Carlos, California. In July 2025, CARGO Therapeutics entered a definitive merger agreement with Concentra Biosciences, LLC, under which Concentra will acquire the company for $4.379 per share in cash plus contingent value rights, with the transaction expected to close in August 2025 following a strategic review amid halted development of certain CAR T therapies and staff reductions.
Shareholder Alert: The Ademi Firm Investigates Whether CARGO Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGX
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZB
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CARGO Therapeutics, Inc. (NASDAQ: CRGX)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX and WNS on Behalf of Shareholders
CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGX
Shareholder Alert: The Ademi Firm investigates whether CARGO Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
CRGX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CARGO Therapeutics, Inc. Is Fair to Shareholders
CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right
CARGO Therapeutics Provides Corporate Update
An Investigation Has Commenced on Behalf of CARGO Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRGX Losses.
Lost Money on CARGO Therapeutics, Inc.(CRGX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
CARGO Therapeutics, Inc. (CRGX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX
Levi & Korsinsky Reminds Shareholders of an Investigation into CARGO Therapeutics, Inc. (CRGX) Regarding Potential Securities Fraud Allegations
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX